LONG MINI-FUTURE - GENMAB | Market Closed - Boerse Frankfurt Warrants 02:04:02 2024-07-16 pm EDT | ||
| 3.64 EUR | +10.30% |
|
| Current month | +47.97% | ||
| 1 month | +3.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 3.64 | +10.30% |
| 24-07-15 | 3.3 | -12.93% |
| 24-07-12 | 3.79 | +21.86% |
| 24-07-11 | 3.11 | +19.16% |
| 24-07-10 | 2.61 | -4.40% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 02:04 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP13K0 |
| ISIN | DE000VP13K09 |
| Date issued | 2020-03-31 |
| Strike | 1,560 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.85 € |
|---|---|
| Lowest since issue | 0.69 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,828
DKK
Average target price
2,446
DKK
Spread / Average Target
+33.83%
- Stock Market
- Certificates
- Certificat
